Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
All the PHP1 patients were under medication of vitamin D and calcium at time of recruitment.Demographic characteristics and basic biochemical features of PHP1, normal control and PHPT groupPHP1 (n = 49)Normal control (n = 30)PHPT (n = 64)p1p2p3M/F (n/n)26/2314/1613/510.8180.0140.001Age (years)25.1 ± 10.826.3 ± 11.255.5 ± 14.30.658 < 0.001 < 0.001 < 18 yo [n, (%)]11 (22.4%)9 (30%)0 (0%)1.0000.0040.001 ≥ 18 yo [n, (%)]38 (77.5%)21 (70%)64 (100%)BMI (kg/m2)23.88 ± 5.2321.72 ± 3.0723.88 (19.47 to 32.24)0.1170.0040.308Overweight [n, (%)]11 (22.4%)6 (20%)25 (29.1%)0.130: : Obese [n, (%)]7 (14.3%)0 (0%)16 (18.6%)Overweight/obese [n, (%)]18 (36.7%)6 (20%)41 (64.1%)0.207 < 0.0010.004Ca (mmol/L)2.24 (1.43 to 2.50)2.42 ± 0.072.78 ± 0.180.048 < 0.001 < 0.001P (mmol/L)1.53 ± 0.371.19 ± 0.140.87 (0.45 to 1.20)0.002 < 0.001 < 0.001ALP (U/L)76.0 (37.0 to 443.0)58.2 ± 15.3102.0 (54.0 to 673.0) < 0.001 < 0.001 < 0.00124hUCa (mmol)1.69 (0.10 to 7.90,n = 42)NA7.48 ± 3.13: : < 0.001β-CTX (ng/ml)0.34 (0.08 to 2.90)0.12 (0.07 to 0.34)0.74 (0.05 to 3.22) < 0.001 < 0.0010.10825OHD (ng/ml)30.95 (10.30 to 136.90)19.16 ± 10.2717.69 ± 8.980.0031.000 < 0.001TP1NP (ng/ml)54.0 (23.9 to 1141.0)56.7 (23.8 to 99.3)67.7 (13.1 to 651.1)0.4200.1260.553PTH (pg/ml)138.20(10.0 to 630.3)37.78 ± 9.58141.85 (55.7 to 756.7) < 0.001 < 0.0010.181Cr (μmol/L)67.69 ± 17.6374.30 ± 17.0061.5 (40 to 134)0.5310.0240.129Alb (g/L)47(31 to 53)46.00 ± 2.2745.23 ± 2.730.3250.1840.022ALT (U/L)16 (7 to 68)20.83 ± 9.6117 (7 to 102)0.1411.0000.022PHP1: pseudohypoparathyroidism type 1; PHPT: primary hyperparathyroidism; M: male; F: female; BMI: body mass index; Ca: serum calcium; P: phosphorus; ALP: alkaline phosphatase; 24hUCa: 24-h urinary calcium; β-CTX: β-C-terminal telopeptide; 25OHD: 25-hydroxy vitamin D; TP1NP: total procollagen type 1 N-peptide; PTH: parathyroid hormone; Cr: creatinine; Alb: albumin; ALT: alanine aminotransferase; p1: p-value for comparison between PHP1 and normal control; p2: p-value for comparison between PHPT and normal control; p3: p-value for comparison between PHP1 and PHPT. p-value of less than 0.05 would be considered as of significantly difference
Source: Clinical characteristics and basic biochemical features of all subjects. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
PHP1 patients as well as PHPT patients were recruited at the out-patient division of Endocrinology, Peking Union Medical College Hospital.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Explorative research on glucolipid metabolism and levels of adipokines in pseudohypoparathyroidism type 1 patients
Study design awaiting verification · Orphanet Journal of Rare Diseases · 2023
Original publication title
Explorative research on glucolipid metabolism and levels of adipokines in pseudohypoparathyroidism type 1 patients
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Pseudohypoparathyroidism type 1 (PHP1) is a rare disease featuring hypocalcemia and elevated PTH level. Though disturbed calcium and phosphorus metabolism under PTH resistant have been widely studied, glucolipid metabolism abnormalities observed in PHP1 patients have received little attention. The aim of this research is to explore the glucolipid metabolism features in a rather large cohort of PHP1 patient. In the current study, PHP1 patients and primary hyperparathyroidism patients as well as normal control were recruited for the investigation. Glucolipid metabolic indices as well as the level of four adipokines were examined.
Source: BackgroundAbstract: Results
A total of 49 PHP1 patients, 64 PHPT patients and 30 healthy volunteers were enrolled. A trend of higher HOMA-β index was found in PHP1 patients than normal controls (median 97.08% vs 68.19%, p = 0.060). Both the PHP1 and PHPT group presented with significantly lower TNFα level compared to normal controls (average 10.74 pg/ml and 12.53 pg/ml vs 15.47 pg/ml, p = 0.002 and 0.041, respectively). FGF21 level was significantly higher in PHPT group than in PHP1 group (median 255.74 pg/ml vs 167.46 pg/ml, p = 0.019).
No significant difference in glucolipid metabolic indices and adipokines was found between PHP1A or PHP1B patients and normal controls, while overweight/obese PHP1 patients tended to have higher leptin than normal-BMI cases (p = 0.055). Multiple linear regression analysis showed BMI rather than PTH or HOMA-IR to be an independent variable of leptin in PHP1.
Source: ResultsAbstract: Conclusion
Metabolic stress given upon especially overweight PHP1 patients may resulted in possible β-cell compensation. Elevated TNFα may be related with hyper-PTH level regardless of calcium level.
Source: ConclusionAuthors’ abstract
Background
Pseudohypoparathyroidism type 1 (PHP1) is a rare disease featuring hypocalcemia and elevated PTH level. Though disturbed calcium and phosphorus metabolism under PTH resistant have been widely studied, glucolipid metabolism abnormalities observed in PHP1 patients have received little attention. The aim of this research is to explore the glucolipid metabolism features in a rather large cohort of PHP1 patient. In the current study, PHP1 patients and primary hyperparathyroidism patients as well as normal control were recruited for the investigation. Glucolipid metabolic indices as well as the level of four adipokines were examined.
Results
A total of 49 PHP1 patients, 64 PHPT patients and 30 healthy volunteers were enrolled. A trend of higher HOMA-β index was found in PHP1 patients than normal controls (median 97.08% vs 68.19%, p = 0.060). Both the PHP1 and PHPT group presented with significantly lower TNFα level compared to normal controls (average 10.74 pg/ml and 12.53 pg/ml vs 15.47 pg/ml, p = 0.002 and 0.041, respectively). FGF21 level was significantly higher in PHPT group than in PHP1 group (median 255.74 pg/ml vs 167.46 pg/ml, p = 0.019).
No significant difference in glucolipid metabolic indices and adipokines was found between PHP1A or PHP1B patients and normal controls, while overweight/obese PHP1 patients tended to have higher leptin than normal-BMI cases (p = 0.055). Multiple linear regression analysis showed BMI rather than PTH or HOMA-IR to be an independent variable of leptin in PHP1.
Conclusion
Metabolic stress given upon especially overweight PHP1 patients may resulted in possible β-cell compensation. Elevated TNFα may be related with hyper-PTH level regardless of calcium level.
Publication and source details
Original title: Explorative research on glucolipid metabolism and levels of adipokines in pseudohypoparathyroidism type 1 patients
Yi Yang; An Song; Fengying Gong; Yan Jiang; Mei Li; Weibo Xia; Xiaoping Xing; Ou Wang; Hui Pan
Orphanet Journal of Rare Diseases · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100001809National Natural Science Foundation of China8187364182070817Xing Xiaoping Wang OuRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T14:45:39.912951+00:00
DOI: 10.1186/s13023-023-02979-w · PMC10683200